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Introduction
The risks and benefits of taking hormone replacement therapy
(HRT) for more than five years are uncertain. There are no
large long-term randomised placebo-controlled trials to guide
the duration of therapy. Large trials are expensive, difficult to
run and can only examine a limited number of regimens and
routes of HRT.
Until the results of large trials (see box on facing page) are
reported we can only guess at the potential primary effect
of HRT on major postmenopausal morbidity and mortality
from the much weaker designs of observational studies (cohort
and case control). These trials are not randomised and are open
to bias and confounding. When the results of observational
trials are expressed as relative risk, there is generally less
chance of a result being due to bias or confounding if the
relative risk is more than halved (<0.5) or more than doubled
(>2.0). The increased relative risk of lung cancer in smokers
is 43.0 and thus the association is very strong. Hot flushes are
reduced by HRT to a relative risk of 0.2. Both results suggest
the findings are likely to be causally related. A relative risk of
1.0 suggests no effect either way.
Breast cancer
A reanalysis of the data from 51 observational studies showed
a relative risk of 1.023 (95% CI* 1.01–1.04) for each year of
HRT use. The relative risk for HRT use of five years or longer
(average 11 years) was 1.35 (95% CI 1.21–1.49).1 These small
increases in relative risk (i.e. under 2.0) could be due to
detection bias, for example the HRT users could have had
more breast examinations and mammograms. HRT users also
have more independent risk factors, such as higher social
class, Western diet, fewer pregnancies, later first pregnancy,
and a higher alcohol intake, which could also account for small
changes in the relative risk of breast cancer. However, if the
increased risk is real it would equate to an extra two detected
breast cancers per 1000 women who use HRT for five years.
Paradoxically, most observational studies show a significant
reduction in deaths from breast cancer in HRT users. Selection
and detection bias can confound all these results.
There is no good evidence that HRT users with a family
history of breast cancer further increase their risk compared to
non-users with a similar history. Women taking HRT do not
need to have mammography more often than other women.
Recent observational studies on the role of added cyclical and
continuous progestogens given with oestrogen therapy have
not clarified if these regimens have any effect on breast cancer
rates.2,3 The relative risks were again small in both studies with
overlap of the confidence intervals for oestrogen alone versus
oestrogen/progestogen regimens. Thus, no recommendations
can yet be made as to whether added progestogens influence
breast cancer risk.
Bowel cancer
The most recent meta-analysis of 23 observational trials
suggests that in postmenopausal women who have ever
taken HRT the relative risk is 0.80 (95% CI 0.72–0.92).4 This
is a 20% reduction in colorectal cancer, however this
result is open to the biases of non-randomisation. The effect
needs to be confirmed in long-term randomised placebo-
controlled trials.
Endometrial cancer
The relative risk that taking unopposed oestrogen for
10 years causes endometrial cancer is 9.5 (95% CI 7.40–
* CI = confidence interval
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12.30) and so this is likely to be a true effect. Additional
progestogen greatly reduces this risk, but the degree of this
protection is not accurately known. Currently the recommended
regimen for women with a uterus is to take oestrogen and
cyclical progestogens before the menopause and for 1–2 years
after menopause. Continuous combination therapy can be
introduced after four years of cyclical therapy or when the
woman is definitely postmenopausal. This reduces the amount
of initial bleeding that is normally seen for several months
when commencing a combined continuous HRT regimen.
Thromboembolism
Current observational studies suggest that although this is a
relatively rare potential complication, the absolute risk rises
from 1 in 10 000 to 3 in 10 000 in HRT users (relative risks in
four studies ranged from 2.1–6.9). A past history of
thromboembolism before the menopause is not an absolute
contraindication to postmenopausal HRT, but might prompt
the prescriber to consider testing for thrombophilia.5
Cardiovascular disease
Observational and animal studies suggest a potential benefit
for HRT. A recent meta-analysis of these epidemiological
studies reports a relative risk of 0.70 (95% CI 0.65–0.75) for
oestrogen therapy alone and 0.66 (0.53–0.84) for combined
HRT.6 However, many researchers argue that the studies have
the potential bias of a ‘healthy user’ effect. A three-year
randomised placebo-controlled trial (PEPI)7 has suggested a
potential benefit in the primary prevention of ischaemic heart
disease. Secondary prevention studies do not suggest that
HRT can reverse the early risk of established ischaemic heart
disease.8 Currently HRT may be offered to women with risk
factors as a potential (but not established) primary
cardioprotective agent to complement other established drug
therapies and lifestyle changes.
Stroke
HRT was not consistently associated with a change in the
relative risk of stroke in observational studies.
Osteoporosis
Short-term randomised controlled trials consistently show
that HRT improves low bone density, and when used
prophylactically it inhibits loss of bone after the menopause.
However, long-term randomised trials are still needed to show
that improved bone density results in a major reduction in
osteoporotic fractures, particularly at the hip. Improvements
in surrogate end-points suggest that a reduced risk of
fractures will be one of the main benefits of taking oestrogen
for many years.
All therapies for osteoporosis require long-term compliance
to achieve their effect. In South Australia in 1997 the
median length of use in all women on HRT was five years
with 70% continuance rate at five years. In women with a
diagnosis of osteoporosis the median length of use was
six years.9
Alzheimer’s dementia
A meta-analysis of 10 observational studies showed a
reduction of this dementia in HRT users. The relative risk
was 0.71 (CI 0.52–0.98).10 Although there are plausible
neuroprotective mechanisms for HRT, long-term randomised
placebo-controlled trials are awaited to see if HRT has a
primary preventative role in this disease which is becoming
more common with increasing longevity. A recent secondary
prevention trial does not suggest that HRT can reverse
established disease.11
Other risks and benefits
Potential long-term risks still need to be defined by long-term
randomised controlled trials. They include increased risks of
gall bladder and uterine surgery.
Other potential benefits may include a reduction in tooth loss,
dry eyes, dry skin, arthritic symptoms, urge incontinence,
frequency, nocturia, urinary tract infections, dry vagina,
dyspareunia, memory loss and possibly some types of
depression. All of these need to be assessed in large trials, but
if a woman experiences sustained symptom relief from HRT
then long-term therapy may be appropriate to maintain her
quality of life.
Current options for length of HRT use
With all the caveats about the weaknesses of observational
data, these data are all we can use when advising a woman
about the potential risks and benefits of long-term HRT. Until
the results of the Women’s Health Initiative and WISDOM are
available it is not possible to make general recommendations
for the duration of treatment. Probably, for menopausal
New randomised placebo-controlled long-term trials
Two large randomised controlled trials have recently
commenced. The Women’s Health Initiative includes
27 000 American women who will receive HRT or placebo
treatment. It is a nine-year study which started two years
ago with funding of nearly US$1 billion. The other primary
prevention study of HRT is the Women’s International
Study of long Duration Oestrogen after Menopause
(WISDOM). It is a placebo-controlled study of women
taking oestrogen, or oestrogen and progestogen for
10 years with a further 10-year follow-up of clinical end-
points such as fracture, cardiac events, cancer, dementia,
thromboembolism, quality of life and death. WISDOM
will enrol 36 200 women internationally. In the UK,
WISDOM is funded for 22 000 entrants, and funding for a
cohort of 2000 Australian women is currently being
sought to contribute to this important trial. This collaboration
will help validate the extrapolation of the results of
WISDOM to the Australian population.
92
Australian Prescriber Vol. 23 No. 5  2000
Self-test questions
The following statements are either true or false
(answers on page 111)
1. Hormone replacement therapy increases the risk
of stroke.
2. Women taking hormone replacement therapy should
have mammography more often than other women.
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